Stoneridge Investment Partners LLC Makes New Investment in Boston Scientific Corporation $BSX

Stoneridge Investment Partners LLC bought a new position in Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 15,486 shares of the medical equipment provider’s stock, valued at approximately $724,000.

Other institutional investors have also recently made changes to their positions in the company. FWL Investment Management LLC purchased a new position in Boston Scientific in the 2nd quarter worth approximately $26,000. Swiss RE Ltd. bought a new position in Boston Scientific in the 4th quarter valued at approximately $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific during the 4th quarter valued at $26,000. Clal Insurance Enterprises Holdings Ltd purchased a new stake in Boston Scientific during the 1st quarter valued at $28,000. Finally, Sfam LLC bought a new stake in shares of Boston Scientific in the 4th quarter worth $29,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

Shares of BSX opened at $51.77 on Friday. The firm has a fifty day simple moving average of $46.06 and a two-hundred day simple moving average of $59.35. The firm has a market cap of $75.02 billion, a PE ratio of 20.96, a P/E/G ratio of 1.13 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same period last year, the business posted $0.75 EPS. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current year.

Boston Scientific announced that its Board of Directors has approved a share buyback plan on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Insider Transactions at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney purchased 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Cheryl Pegus acquired 1,770 shares of the stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the purchase, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 204,322 shares of company stock worth $9,939,221 in the last ninety days. Insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BSX. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research note on Thursday, May 28th. Weiss Ratings downgraded Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, July 7th. TD Cowen decreased their target price on Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 price target on shares of Boston Scientific in a report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: An investment analysis argues that Boston Scientific could recover from its recent headwinds, supporting the view that the company’s diversified portfolio and structural-growth markets can reaccelerate over time. Boston Scientific: A Deep Dive Into The Headwinds And Why I See A Recovery Ahead
• Positive Sentiment: Analyst consensus remains broadly favorable, with brokerage recommendations suggesting that BSX may merit portfolio consideration. However, the article cautions that sell-side ratings can be overly optimistic and should not be used as the sole investment signal. Brokers Suggest Investing in Boston Scientific
• Neutral Sentiment: Recent fund commentary highlights Boston Scientific’s second-quarter performance and the factors that affected the stock, giving investors additional context on the company’s operating challenges but offering no new company guidance or specific catalyst. Here’s What Hurt Boston Scientific Corporation in Q2
• Negative Sentiment: Parnassus Investments identified a growth slowdown in key Boston Scientific businesses. That raises concerns about near-term revenue momentum and could pressure the stock if weaker growth persists, despite the company’s recent earnings beat and positive longer-term outlook. Boston Scientific Faces Growth Slowdown in Key Businesses

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.